Search research articles
Contact Us
Filters
Showing results (11-20 of 28) with videos related to
Page
of 3
Sort By:
EJNMMI Radiopharmacy and Chemistry
|
May 30, 2025
Selection of the optimal chelator for labeling of DARPin Ec1 with gallium-68 for PET imaging of EpCAM expression
Anzhelika Vorobyeva, Moeen-Ud Din, Alexey Schulga, et al.
International Journal of Molecular Sciences
|
December 11, 2022
Direct In Vivo Comparison of <sup>99m</sup>Tc-Labeled Scaffold Proteins, DARPin G3 and ADAPT6, for Visualization of HER2 Expression and Monitoring of Early Response for Trastuzumab Therapy
Vladimir Tolmachev, Vitalina Bodenko, Maryam Oroujeni, et al.
International Journal of Biological Macromolecules
|
December 22, 2019
Effect of a radiolabel biochemical nature on tumor-targeting properties of EpCAM-binding engineered scaffold protein DARPin Ec1
Sergey M Deyev, Anzhelika Vorobyeva, Alexey Schulga, et al.
Cancers
|
August 27, 2021
Imaging-Guided Therapy Simultaneously Targeting HER2 and EpCAM with Trastuzumab and EpCAM-Directed Toxin Provides Additive Effect in Ovarian Cancer Model
Tianqi Xu, Anzhelika Vorobyeva, Alexey Schulga, et al.
Scientific Reports
|
June 30, 2019
Optimal composition and position of histidine-containing tags improves biodistribution of <sup>99m</sup>Tc-labeled DARPin G3
Anzhelika Vorobyeva, Alexey Schulga, Elena Konovalova, et al.
International Journal of Molecular Sciences
|
April 27, 2024
Preclinical Evaluation of HER2-Targeting DARPin G3: Impact of Albumin-Binding Domain (ABD) Fusion
Sergey M Deyev, Maryam Oroujeni, Javad Garousi, et al.
Molecular Pharmaceutics
|
January 5, 2019
Comparative Evaluation of Two DARPin Variants: Effect of Affinity, Size, and Label on Tumor Targeting Properties
Sergey Deyev, Anzhelika Vorobyeva, Alexey Schulga, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
August 13, 2021
Phase I Trial of <sup>99m</sup>Tc-(HE)<sub>3</sub>-G3, a DARPin-Based Probe for Imaging of HER2 Expression in Breast Cancer
Olga Bragina, Vladimir Chernov, Alexey Schulga, et al.
Molecular Pharmaceutics
|
April 1, 2024
Comparative Preclinical Evaluation of HYNIC-Modified Designed Ankyrin Repeat Proteins <i>G3</i> for the <sup>99m</sup>Tc-Based Imaging of HER2-Expressing Malignant Tumors
Maria Larkina, Ruslan Varvashenya, Feruza Yuldasheva, et al.
International Journal of Molecular Sciences
|
June 13, 2025
Targeting of Epithelial Cell Adhesion Molecule-Expressing Malignant Tumors Using an Albumin-Binding Domain-Fused Designed Ankyrin Repeat Protein: Effect of the Molecular Architecture
Vladimir Tolmachev, Anzhelika Vorobyeva, Alia Hani Binti Rosly, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 28) with videos related to
Sort By:
Page
of 3
EJNMMI Radiopharmacy and Chemistry
|
May 30, 2025
Selection of the optimal chelator for labeling of DARPin Ec1 with gallium-68 for PET imaging of EpCAM expression
Anzhelika Vorobyeva, Moeen-Ud Din, Alexey Schulga, et al.
International Journal of Molecular Sciences
|
December 11, 2022
Direct In Vivo Comparison of <sup>99m</sup>Tc-Labeled Scaffold Proteins, DARPin G3 and ADAPT6, for Visualization of HER2 Expression and Monitoring of Early Response for Trastuzumab Therapy
Vladimir Tolmachev, Vitalina Bodenko, Maryam Oroujeni, et al.
International Journal of Biological Macromolecules
|
December 22, 2019
Effect of a radiolabel biochemical nature on tumor-targeting properties of EpCAM-binding engineered scaffold protein DARPin Ec1
Sergey M Deyev, Anzhelika Vorobyeva, Alexey Schulga, et al.
Cancers
|
August 27, 2021
Imaging-Guided Therapy Simultaneously Targeting HER2 and EpCAM with Trastuzumab and EpCAM-Directed Toxin Provides Additive Effect in Ovarian Cancer Model
Tianqi Xu, Anzhelika Vorobyeva, Alexey Schulga, et al.
Scientific Reports
|
June 30, 2019
Optimal composition and position of histidine-containing tags improves biodistribution of <sup>99m</sup>Tc-labeled DARPin G3
Anzhelika Vorobyeva, Alexey Schulga, Elena Konovalova, et al.
International Journal of Molecular Sciences
|
April 27, 2024
Preclinical Evaluation of HER2-Targeting DARPin G3: Impact of Albumin-Binding Domain (ABD) Fusion
Sergey M Deyev, Maryam Oroujeni, Javad Garousi, et al.
Molecular Pharmaceutics
|
January 5, 2019
Comparative Evaluation of Two DARPin Variants: Effect of Affinity, Size, and Label on Tumor Targeting Properties
Sergey Deyev, Anzhelika Vorobyeva, Alexey Schulga, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
August 13, 2021
Phase I Trial of <sup>99m</sup>Tc-(HE)<sub>3</sub>-G3, a DARPin-Based Probe for Imaging of HER2 Expression in Breast Cancer
Olga Bragina, Vladimir Chernov, Alexey Schulga, et al.
Molecular Pharmaceutics
|
April 1, 2024
Comparative Preclinical Evaluation of HYNIC-Modified Designed Ankyrin Repeat Proteins <i>G3</i> for the <sup>99m</sup>Tc-Based Imaging of HER2-Expressing Malignant Tumors
Maria Larkina, Ruslan Varvashenya, Feruza Yuldasheva, et al.
International Journal of Molecular Sciences
|
June 13, 2025
Targeting of Epithelial Cell Adhesion Molecule-Expressing Malignant Tumors Using an Albumin-Binding Domain-Fused Designed Ankyrin Repeat Protein: Effect of the Molecular Architecture
Vladimir Tolmachev, Anzhelika Vorobyeva, Alia Hani Binti Rosly, et al.
Page
of 3